Intended for healthcare professionals

Research News

PCSK9 inhibitors reduce cardiovascular events, preliminary data show

BMJ 2015; 350 doi: (Published 17 March 2015) Cite this as: BMJ 2015;350:h1508
  1. Susan Mayor
  1. 1London

Two investigational drugs from a new class of lipid lowering agents—the proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors—significantly reduce cardiovascular events, new exploratory analyses have shown.

PCSK9 promotes the degradation of low density lipoprotein (LDL) receptors, so blocking its action increases the levels of receptor, which facilitates the clearance of LDL cholesterol.

The studies, reported in the New England Journal of Medicine, investigated the efficacy and safety of two monoclonal antibodies that inhibit PCSK9 and showed that they …

View Full Text

Log in

Log in through your institution


* For online subscription